Media

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

August 7, 2026

IPO

Latigo

Latigo IPO raises nearly $350M for pain drug development

June 18, 2026

Financing Event

Triveni Bio

Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies

May 8, 2026

Financing Event

Odyssey Therapeutics

Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs

April 7, 2026

Exit

Tubulis

Gilead to acquire Tubulis GmbH for up to $5 billion to further strenghten oncology pipeline

February 5, 2026

Financing Event

Angitia

Angitia raises $130M to challenge Amgen with bone-building bispecifics

December 3, 2025

Financing Event

TRIANA Biomedicines

Pfizer-backed Triana scores $120M Series B to take molecular glue degrader into the clinic

November 10, 2025

Financing Event

Iambic Therapeutics

Iambic Raises Over $100M in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics

October 15, 2025

Financing Event

Tubulis

Tubulis snags $361M for clinical-stage ADCs

October 9, 2025

Other News

Ascenta Capital

Ascenta Capital Announces Final Close of $325 Million Inaugural Fund to Back Development-Stage Biotechs

September 10, 2025

Financing Event

Odyssey Therapeutics

Odyssey Therapeutics heralds $213M Series D to strengthen clinical portfolio

May 14, 2025

Financing Event

ADARx Pharmaceuticals

AbbVie pays ADARx $335M cash for next-gen siRNA options

October 23, 2024

Financing Event

Alpha-9 Oncology

Alpha-9 Oncology Inc. announces $175M oversubscribed Series C

September 6, 2024

Financing Event

OrsoBio

OrsoBio announces oversubscribed $67M Series B financing to accelerate mitochondrial protonophore portfolio

July 16, 2024

Financing Event

Cardurion Pharmaceuticals

Cardurion Pharmaceuticals announces $260M Series B financing (Business Wire)

June 18, 2024

Other News

Iambic Therapeutics

How two academic chemists turned San Diego startup Iambic into an AI force (Endpoints)

March 18, 2024

Other News

Iambic Therapeutics

NVIDIA GTC 2024 — Official Keynote Intro

December 5, 2023

Financing Event

Odyssey Therapeutics

Gary Glick's Odyssey raises $101M Series C as first immunology drugs approach the clinic (Endpoints)

December 5, 2023

Financing Event

Odyssey Therapeutics

Odyssey raises epic $101M to push preclinical programs into the clinic (Fierce)

December 5, 2023

Financing Event

Odyssey Therapeutics

Odyssey Therapeutics announces $101M Series C financing (Business Wire)

October 4, 2023

Financing Event

Alpha-9 Oncology

Alpha-9 Oncology Inc. announces $175M oversubscribed Series C

October 3, 2023

Financing Event

Iambic Therapeutics

Iambic Therapeutics announces close of oversubscribed $100M Series B financing (Business Wire)

August 21, 2023

Financing Event

ADARx Pharmaceuticals

ADARx to use $200M in financing to advance its clinical programs (Angioedema News)

August 10, 2023

Financing Event

ADARx Pharmaceuticals

ADARx secures $200M to advance clinical programmes (Pharmaceutical Technology)

January 21, 2023

Other News

ADARx Pharmaceuticals

Jan. 20 Quick Takes: Moderna vets pick ADARx for new VC's debut investment (BioCentury)

No results

This is the time to invest

The global convergence of biological and chemical insights, life science technology, data analytics, talent, and capital is unprecedented.

info@ascentacap.com